Lipid Abnormalities (Dyslipidemia)

What is Lipid Abnormalities?

Lipid abnormalities, also known as dyslipidemia, refer to any deviation from the normal range of blood lipids (fats). The most commonly measured lipids are:

• Low‑density lipoprotein cholesterol (LDL‑C) – “bad” cholesterol that can deposit in arterial walls.
• High‑density lipoprotein cholesterol (HDL‑C) – “good” cholesterol that helps remove excess cholesterol from arteries.
• Triglycerides – a type of fat that the body uses for energy; very high levels increase cardiovascular risk.
• Total cholesterol – the sum of LDL, HDL, and a portion of triglycerides.

When any of these values are too high or too low, the condition is called a lipid abnormality. Dyslipidemia is a major, modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), stroke, and peripheral artery disease.¹

Common Causes

Both genetic and acquired factors can upset the delicate balance of blood lipids. Below are the most frequent contributors:

• Familial hypercholesterolemia (FH) – an inherited mutation that reduces the liver’s ability to remove LDL‑C.
• Dietary patterns high in saturated fats, trans fats, and refined carbohydrates.
• Obesity and visceral fat accumulation – especially central (abdominal) obesity.
• Type 2 diabetes mellitus – insulin resistance raises triglycerides and lowers HDL‑C.
• Hypothyroidism – reduced thyroid hormone slows lipid metabolism.
• Chronic kidney disease (CKD) – alters lipoprotein synthesis and clearance.
• Medications such as glucocorticoids, antiretroviral therapy, certain diuretics, and beta‑blockers.
• Excessive alcohol intake – can sharply raise triglyceride levels.
• Pregnancy – hormonal changes may temporarily increase triglycerides.
• Metabolic syndrome – a cluster of hypertension, hyperglycemia, abdominal obesity, and dyslipidemia.

Associated Symptoms

In most cases, lipid abnormalities are silent and discovered during routine blood work. When symptoms do appear, they are usually indirect, reflecting the complications of prolonged dyslipidemia:

• Xanthomas – yellowish cholesterol deposits on tendons or skin (more common with familial forms).
• Arcus senilis – a whitish-gray ring around the cornea, seen in severe hypercholesterolemia.
• Chest pain or angina – indicates coronary artery disease caused by plaque buildup.
• Shortness of breath on exertion, fatigue, or reduced exercise tolerance.
• Transient ischemic attacks (TIA) or stroke symptoms – sudden weakness, speech difficulty, or vision loss.
• Pain or cramping in the legs while walking (claudication) – a sign of peripheral artery disease.

Because these manifestations often arise only after years of untreated dyslipidemia, regular screening is essential.

When to See a Doctor

Schedule an appointment promptly if you notice any of the following:

• Family history of premature heart attack or stroke (men < 55 y, women < 65 y).
• Personal history of diabetes, hypertension, or obesity.
• Persistent fatigue, unexplained shortness of breath, or chest discomfort.
• Visible yellowish skin lesions (xanthomas) or a white ring around the cornea.
• Recent significant weight gain, especially around the abdomen.
• Being on medications known to affect lipids and not having a recent lipid panel.

Even in the absence of symptoms, the American Heart Association recommends a lipid panel at least once every 4‑6 years for adults, and earlier for high‑risk individuals.²

Diagnosis

Diagnosing dyslipidemia involves a combination of laboratory testing, risk assessment, and sometimes imaging.

1. Laboratory Evaluation

• Fasting lipid panel – drawn after an 8‑12 hour fast; reports total cholesterol, LDL‑C, HDL‑C, and triglycerides.
• Non‑fasting lipid profile – increasingly accepted for routine screening; triglycerides may be slightly higher.
• Apolipoprotein B (ApoB) – measures the number of atherogenic particles; useful in high‑risk patients.
• Lipoprotein(a) [Lp(a)] – an independent genetic risk factor for ASCVD.
• Thyroid‑stimulating hormone (TSH) – to rule out hypothyroidism.
• Fasting glucose or HbA1c – to assess for diabetes.

2. Risk Stratification

Clinicians use tools such as the ASCVD risk calculator (American College of Cardiology/AHA) to gauge 10‑year heart‑attack or stroke risk, incorporating age, sex, race, blood pressure, smoking status, and lipid values.³

3. Imaging (when indicated)

• Coronary artery calcium (CAC) scoring – CT scan that quantifies calcified plaque.
• Carotid ultrasound – detects intima‑media thickness and plaques.

4. Genetic Testing

For suspected familial hypercholesterolemia or other inherited disorders, clinicians may order LDLR, APOB, or PCSK9 gene panels.

Treatment Options

Treatment is individualized based on the type and severity of the lipid abnormality, overall cardiovascular risk, and patient preferences.

1. Lifestyle Modifications (First‑line for most patients)

• Heart‑healthy diet – Emphasize fruits, vegetables, whole grains, legumes, nuts, and fatty fish; limit saturated fat (< 7% of total calories), eliminate trans fats, and keep added sugars low.
• Weight management – Aim for a 5‑10% weight loss if overweight; even modest loss improves LDL‑C and triglycerides.
• Physical activity – At least 150 minutes of moderate aerobic exercise or 75 minutes of vigorous activity per week, plus resistance training twice weekly.
• Alcohol moderation – No more than 1 drink/day for women and 2 for men; avoid binge drinking.
• Smoking cessation – Improves HDL‑C and reduces overall risk.

2. Pharmacologic Therapy

Medication selection follows guideline‑based algorithms (ACC/AHA 2019, ESC 2021). Common drug classes include:

• Statins (HMG‑CoA reductase inhibitors) – First‑line; lower LDL‑C by 20‑60% and modestly raise HDL‑C. Examples: atorvastatin, rosuvastatin.⁴
• Ezetimibe – Inhibits intestinal cholesterol absorption; added when statin alone is insufficient.
• PCSK9 inhibitors (evolocumab, alirocumab) – Monoclonal antibodies that can reduce LDL‑C > 60%; indicated for FH or high‑risk patients not at target.
• Bile‑acid sequestrants (cholestyramine, colesevelam) – Lower LDL‑C; may raise triglycerides, used when statins are contraindicated.
• Fibrates (gemfibrozil, fenofibrate) – Primarily lower triglycerides and modestly raise HDL‑C.
• Omega‑3 fatty acid prescriptions (e.g., icosapent ethyl) – Significantly drop high triglycerides and have cardiovascular outcome benefit.
• Niacin (vitamin B3) – Can raise HDL‑C but limited by side effects; rarely used now.

3. Management of Underlying Conditions

Addressing secondary causes is crucial:

• Treat hypothyroidism with levothyroxine.
• Optimize glycemic control in diabetes (metformin, SGLT2 inhibitors, GLP‑1 agonists).
• Adjust or replace offending medications (e.g., switch from a high‑risk antiretroviral to a newer regimen).

4. Follow‑Up and Monitoring

After initiating therapy, lipid panels are typically repeated at 4‑12 weeks to gauge response, then annually once stable. Liver enzymes and creatine kinase are monitored with statins, especially at higher doses.

Prevention Tips

Because many lipid abnormalities are modifiable, adopting preventive habits early can dramatically lower lifelong risk.

• Start a balanced diet in childhood; limit fast food and sugary beverages.
• Encourage regular family activity—walks, bike rides, sports.
• Maintain a healthy body mass index (BMI 18.5‑24.9 kg/m²).
• Get screened according to guidelines—at least once every 4‑6 years for adults, earlier for those with risk factors.
• Know your family history; discuss it with your physician to decide if early genetic testing is warranted.
• Manage stress through mindfulness, adequate sleep, and counseling if needed—chronic stress can affect lipid metabolism.
• Limit processed meats and high‑sodium foods, which often accompany unhealthy fat intake.
• Consider plant sterol/stanol fortified foods (e.g., certain margarines) to modestly reduce LDL‑C.

Emergency Warning Signs

References

1. Mayo Clinic. “Dyslipidemia.” Accessed March 2024. https://www.mayoclinic.org
2. American Heart Association. “Lipid Management Guidelines.” 2023. https://www.heart.org
3. American College of Cardiology/American Heart Association. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.” Circulation. 2020;140:e596‑e646.
4. NIH National Heart, Lung, and Blood Institute. “Statin Side Effects and Safety.” Updated 2022. https://www.nhlbi.nih.gov
5. European Society of Cardiology. “2021 ESC Guidelines on Cardiovascular Disease Prevention.” European Heart Journal. 2021;42:3227‑3337.